在肺高血压中可溶性转激素受体-1 与COPD相关的肺高血压
Oleh Myronenko1,2, Pero Curcic3, Philipp Douschan1,2
1Division of Respiratory Medicine, Lung Research Cluster, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
溶性转移林受体-1 (sTfR1) 与慢性阻塞性肺病 (COPD) 与肺高血压 (PH) 的预后不佳有关. 升高的sTfR1,特别是低血红蛋白,可以识别严重的PH和明显的炎症性COPD表型.
科学领域:
- 肺部医学 肺部医学
- 心血管研究研究心血管研究
- 血液学 血液学 血液学
背景情况:
- 慢性阻塞性肺病 (COPD) 呈现出多种肺血管干扰,从轻度到重度的肺高血压 (PH).
- 铁依赖调节剂,如低氧诱导因子-2 (HIF-2),与COPD的表型变异有关.
- 溶性转移林受体-1 (sTfR1) 在铁平衡中起作用,并且已成为疾病发病的潜在因素.
研究的目的:
- 研究可溶性转激素受体-1 (sTfR1) 在与COPD相关的肺高血压 (PH) 中的诊断和预后作用.
- 根据sTfR1水平和临床参数来识别不同的COPD表型.
- 探索STfR1,铁沉积和COPD中的PH严重程度之间的关系.
主要方法:
- 对接受右心导管治疗的COPD门诊患者的分析.
- 基于stfR1水平和非侵入性临床数据来定义COPD表型的无监督聚类.
- 检查已扩展的COPD末期肺部,检查TfR1表达和铁沉积.
主要成果:
- sTfR1水平与肺动脉平均压力 (mPAP) 和肺血管阻力 (PVR) 有显著的相关性.
- 升高的sTfR1与生存率低下有关,并预测严重的PH,与低血红蛋白相结合时,预测得到改善.
- 集群分析确定了三种COPD表型,其中两种表现出生存能力不佳,一种表现为中度呼吸道阻塞,PH,sTfR1升高,贫血和炎症.
- 肺部爆炸显示TfR1阳性,带铁的细胞 (可能是巨细胞),带铁的细胞密度与中度/重度PH的mPAP负相关.
结论:
- 升高的sTfR1可以预测COPD患者的预后不佳.
- sTfR1,特别是在低血红蛋白的情况下,显示出作为COPD严重PH的生物标志物的潜力.
- 这种组合可能会识别出一种独特的COPD表型,其特点是系统性炎症,贫血和缺铁.
更多相关视频
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
07:45Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization
Published on: January 23, 2019
相关概念视频
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
